The expansion of Sanofi’s vaccine manufacturing site in Val de Reuil, France account for a €170 million investment, according to the company. The new facility will allow to expand the supply of VaxigripTetra®, new quadrivalent influenza vaccine, to up to 70 countries in six continents. The product contains two A strains and two B strains of influenza virus. The new facility will be the only of its kind in France and Sanofi Pasteur remains the sole influenza vaccine producer in the country. Sanofi plans to complete the expansion by 2021, and will begin producing vaccines in this new facility in 2022.